cost-saving approach to triple therapy for hepatitis C using the OPTIM prognostic tool to predict virologic response to 4 weeks of peginterferon and ribavirin in genotype 1 patients
Data de publicación
2013Título da revista
Hepatology
Tipo de contido
Publicación de congreso